Acute PCI for ST-segment elevation myocardial infarction: Is later better than never?

JAMA

Volumn 293, Issue 23, 2005, Pages 2930-2932

  Gibbons, Raymond J ^a   Grines, Cindy L ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT; TICLOPIDINE; ABCIXIMAB; ANTITHROMBOCYTIC AGENT; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY;

BLOOD CLOT LYSIS; BLOOD FLOW; CLINICAL PRACTICE; CLINICAL TRIAL; COLLATERAL CIRCULATION; CONSERVATIVE TREATMENT; DEATH; ECHOCARDIOGRAPHY; EDITORIAL; EMERGENCY HEALTH SERVICE; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; HEART MUSCLE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HOSPITAL; HOSPITAL ADMINISTRATOR; HUMAN; MORTALITY; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK REDUCTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SMOKING CESSATION; ST SEGMENT ELEVATION; STROKE; THORAX PAIN; TREATMENT OUTCOME; NOTE; STENT; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; STENTS; TIME FACTORS;

EID: 20444468939     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.293.23.2930     Document Type: Editorial

References (21)

1. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J. Practice variation and missed opportunities for reperfusion in ST-segmentelevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet. 2002;359:373-377.
2. Grzybowski M, Clements EA, Parsons L, et al. Mortality benefit of immediate revascularization of acute ST-segment elevation myocardial infarction in patients with contraindications to thrombolytic therapy: a propensity analysis. JAMA. 2003; 290:1891-1898.
3. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343:311-322.
4. Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guideline for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol. 2004;44:671-719.
5. Van de Werf F, Ardissino D, Betriu A, et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force on the management of acute myocardial infarction of the European Society of Cardiology. Eur Heart J. 2003;24:28-66.
6. Grines CL, Serruys P, O'Neill WW. Fibrinolytic therapy: is it a treatment of the past? Circulation. 2003;107:2538-2542.
7. Schömig A, Mehilli J, Antoniucci D, et al; for the Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA. 2005;293:2865-2872.
8. Gibbons RJ, Valeti US, Araoz PA, Jaffe AS. The quantification of infarct size. J Am Coll Cardiol. 2004;44:1533-1542.
9. Chareonthaitawee P, Gibbons RJ, Roberts RS, et al; CORE Investigators (Collaborative Organization for RheothRx Evaluation). The impact of time to thrombolytic treatment on outcome in patients with acute myocardial infarction. Heart. 2000;84:142-148.
10. Schömig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction: Stent versus Thrombolysis for Occluded Coronary Arteries in Patients With Acute Myocardial Infarction Study Investigators. N Engl J Med. 2000;343:385-391.
11. Kastrati A, Mehilli J, Dirschinger J, et al. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial: Stent versus Thrombolysis for Occluded Coronary Arteries in Patients With Acute Myocardial Infarction (STOPAMI-2) Study. Lancet. 2002;359:920-925.
12. Van de Werf F. Discrepancies between the effects of coronary reperfusion on survival and left ventricular function. Lancet. 1989;1:1367-1369.
13. Faxon DP, Gibbons RJ, Chronos NAF, et al. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: the results of the HALT-MI study. J Am Coll Cardiol. 2002;40:1199-1204.
14. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation myocardial infarction: a randomized controlled trial. JAMA. 2005;293:1063-1072.
15. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death, 1: myocardial infarct size vs duration of coronary occlusion in dogs. Circulation. 1977;56:786-794.
16. Reimer KA, Jennings RB, Cobb FR, et al. Animal models for protecting ischemic myocardium: results of the NHLBI Cooperative Study: comparison of unconscious and conscious dog models. Circ Res. 1985;56:651-665.
17. Murdock RH, Chu A, Grubb M, Cobb FR. Effects of reestablishing blood flow on extent of myocardial infarction in conscious dogs.Am J Physiol. 1985;249:H783-H791.
18. Christian TF, Schwartz R, Gibbons RJ. Determinants of infarct size in reperfusion therapy for acute myocardial infarction. Circulation. 1992;86:81-90.
19. Clements IP, Christian TF, Higano ST, Gibbons RJ, Gersh BJ. Angioplasty/ coronary heart disease: residual flow to the infarct zone as a determinant of infarct size after direct angioplasty. Circulation. 1993;88:1527-1533.
20. Stone GW, Cox D, Garcia E, et al. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation. 2001;104:636-641.
21. Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA. 2005;293:979-986.